The future of targeted therapies
Advancing cures and transforming lives for patients in need
Device-based Delivery: Extroducer®
The Extroducer is a novel, modality-agnostic endovascular infusion catheter with the ability to delivery payload directly to targeted cardiac and pancreatic tissues and solid tumors.
Cell Therapies
We are developing novel stem cell-based therapies for tissue repair in cardiac failure and Parkinsons’ disease using unique progenitor cell technology.
Modified Cell Therapies
We are currently investigating cell-mediated mRNA therapy technologies as we build out our targeted therapies portfolio.
We are
ScientistsInnovatorsEntrepreneursVisionaries
We combine first-in-class delivery and therapy tech
We are advancing healthcare through innovative cell-based therapies and cutting-edge drug delivery technologies to address critical health needs.
Founded in 2014
Tullinge, Sweden
80+ Employees
20 Nationalities
SmartCella in the news
Första patienten behandlad i XyloCor Therapeutics fas IIb-studiemed SmartCellas leveransplattform Extroducer
First patient dosed in XyloCor Therapeutics’ Phase IIb trial using SmartCella’s Extroducer delivery platform
SmartCella forms Scientific Advisory Board with leading global scientific experts
Explore recent breakthroughs and industry trends
Want to improve the targeting of your therapy?